[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wake Forest University Health Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":591},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,189,0,25,[9,44,66,86,112,136,163,187,208,234,254,277,299,321,349,371,392,418,440,461,484,505,526,548,570],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100471658","phase-4-prophylactic-antibiotic-coated-nail-to-prevent-infection-a-clinical-trial-100471658",false,"NCT05421741","Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial","Inclusion Criteria:\n\n* Patients 18 years or older\n* Gustilo Type II or III open tibia fracture requiring definitive fixation with intramedullary nail\n\nExclusion Criteria:\n\n* Less than 18 years of age\n* Allergy to vancomycin or gentamicin\n* Unable to speak English or Spanish\n* Pregnant and lactating women\n* Prisoner\n* Unable to follow up for 12 months","ALL","18 Years",{"count":19,"type":20},242,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This prospective randomized clinical trial will compare outcomes between patients treated primarily with a prophylactic antibiotic coated nail and those treated with traditional standard of care intramedullary (IM) nailing.",[26,27,28],"Osteomyelitis Tibia","Tibial Fractures","Open Tibia Fracture",[30],"Antibiotic-coated nail","RECRUITING","2026-08-17",{"date":34,"type":35},"2026-08-18","ACTUAL",{"date":37,"type":35},"2023-05-15",{"date":39,"type":20},"2027-12",{"name":41,"class":42},"Wake Forest University Health Sciences","OTHER",15,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100448766","leveraging-social-innovation-and-community-engagement-to-reduce-disparities-in-outbreak-control-outcomes-100448766","NCT05123729","Leveraging Social Innovation and Community-Engagement to Reduce Disparities in Outbreak Control Outcomes","Community-Academic Partnerships to Address Disparities Within Rural and Urban Communities","All individuals aged 18+ years are eligible for study participation. Each phase may have additional requirements, including residency in North Carolina, employment at a local health department, etc. Participants must be able to complete study activities independently and have the capacity to consent to study participation.",true,{"count":53,"type":20},546,"OBSERVATIONAL","This study evaluates the impact of an intervention to increase viral transmission behaviors. The intervention will be developed through a crowdsourcing contest.",[57],"Outbreak Investigation",{"date":59,"type":35},"2026-08-19",{"date":61,"type":35},"2025-04-05",{"date":63,"type":20},"2027-08",{"name":41,"class":42},1,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":21,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":85,"locationsCount":65},"100455569","mri-in-high-grade-glioma-patients-undergoing-chemoradiation-100455569","NCT05212272","MRI in High-Grade Glioma Patients Undergoing Chemoradiation","A Feasibility Study of Interim PET-MRI in High-grade Glioma Patients Undergoing Chemoradiation","Inclusion Criteria:\n\n* Pathologically confirmed diagnosis of high-grade glioma (grade III or IV) or WHO grade II glioma, IDH wildtype (molecular glioblastoma multiforme \\[GBM\\]).\n* ≥18 years of age.\n* ECOG performance status of 0 to 3\n* Anticipated to receive 6 weeks of chemoradiation\n\nExclusion Criteria:\n\n* Does not speak or read English\n* Unable to participate in cognitive testing due to aphasia or other severe cognitive impairment as determined by the PI, or Dr. Cummings or her designee.\n* Unable to give informed consent\n* Past medical history of any kind of dementia or diagnosed with mild cognitive impairment prior to diagnosis with their brain tumor\n* Unable to safely fast for 8 hours prior to bloodwork or 6 hours prior to PET scan\n* Currently taking cognition-enhancing medications including:\n\n  * Donepezil\n  * Memantine\n  * Armodafinil\n  * Methylphenidate\n* Pregnant or nursing mothers.\n* Patients taking blood thinners will be excluded from the optional Lumbar Puncture only, they are eligible for participation in the main study-provided they meet inclusion\u002Fexclusion criteria",{"count":74,"type":20},16,[76],"NA","The purpose of this research study is to see if investigators can predict how brain functioning changes after radiation treatment based on PET scans and blood tests. Most participants experience at least mild decreases in their memory or attention after radiation therapy. Investigators hope that PET scans, optional lumbar puncture, and blood tests might help investigators predict who might have larger changes in their brain function after radiation.",[79],"High Grade Glioma","2026-08-13",{"date":32,"type":35},{"date":83,"type":35},"2022-09-02",{"date":39,"type":20},{"name":41,"class":42},{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100646407","optimizing-sustainable-cuff-access-and-training-pathways-for-self-measured-blood-pressure-monitoring-in-primary-care-100646407","NCT07693699","Optimizing Sustainable Cuff Access and Training Pathways for Self-Measured Blood Pressure Monitoring in Primary Care","Optimizing Sustainable Cuff Access and Training Pathways for Self-Measured Blood Pressure Monitoring in Primary Care: A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosed hypertension documented prior to the index clinic visit.\n* Scheduled for and attends an in-person visit with a participating clinician at a study clinic.\n* Elevated BP (blood pressure) documented in Epic during rooming or the clinic visit before study enrollment, defined as systolic BP \\>=140 mmHg or diastolic BP \\>=90 mmHg.\n\nExclusion Criteria:\n\n* Visit is canceled, rescheduled, or the patient does not attend the visit.\n* Patient already has a usable home BP cuff provide through insurance within the past 5 years.\n* Patient declines assistance obtaining a BP cuff.\n* Patient declines submitting cuff order to insurance.\n* Patient unable to participate for operational reasons.",{"count":94,"type":20},150,[76],"The goal of this study is to identify what cuff delivery and BP log return modality most effectively achieve successful delivery of a self-measured blood pressure (SMBP) intervention in routine care, among adult primary care patients with uncontrolled hypertension?",[98],"Hypertension",[100,101,102],"blood pressure cuff","blood pressure cuff delivery","blood pressure cuff instruction","2026-08-10",{"date":105,"type":35},"2026-08-12",{"date":107,"type":35},"2026-07-30",{"date":109,"type":20},"2026-11-20",{"name":41,"class":42},6,{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":130,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":65},"100616782","allograft-vs-autograft-nonunion-100616782","NCT07310082","Allograft vs. Autograft Nonunion","Allograft vs. Autograft to Improve Timely Return to Duty Following Nonunion","Inclusion Criteria:\n\n* Patients 18 years or older\n* Long bone (tibia, femur, and humerus) nonunion appropriate for either study treatment: to be treated with bone graft harvested from a remote site or using reamer harvester (RIA)\n* Nonunion surgery to be performed at least five months after initial fracture fixation\n* Prior operative fixation of fracture\n* Radiographic apparent bone gap (RABG) of \\>5cm\n\nExclusion Criteria:\n\n* Patient that speaks neither English nor Spanish\n* Patients whose treatment plan includes local autograft only (available callus from the nonunion site or no planned bone graft)\n* Known active infection (defined as any clinical signs or symptoms of active infection, such as fevers, wound redness, warmth, swelling, induration or drainage, and abnormal while blood cell count, erythrocyte sedimentation rate, or C-reactive protein) being treated with antibiotics\n* Body mass index greater than 50\n* Patients unlikely to follow-up due to homelessness, or planning follow-up at another institution\n* Prisoner",{"count":120,"type":20},156,[76],"The purpose of this research study is to find out if patients treated for nonunion fracture with autograft or allograft return to activity faster.",[124],"Nonunion Fracture",[126,127,128],"Allograft","Autograft","Nonunion","NOT_YET_RECRUITING",{"date":105,"type":35},{"date":132,"type":20},"2026-08",{"date":134,"type":20},"2030-12",{"name":41,"class":42},{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":16,"minAge":142,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100608029","comprehensive-care-for-aya-needs-assessment-survey-100608029","NCT07196241","Comprehensive Care for AYA: Needs Assessment Survey","Inclusion Criteria:\n\n* Individuals diagnosed with cancer between the ages of 15-39 per self-report. Participants may be enrolled at any age provided diagnosis was between ages 15-39.\n* Individuals who have received or are receiving cancer-directed treatment (chemotherapy, immunotherapy, surgery and\u002For radiation) at one of the participating centers per self-report.\n\nExclusion Criteria:\n\n* Severe emotional distress or anxiety that would limit compliance with study requirements per self-report.","15 Years",{"count":144,"type":20},300,"The goal of this observational study is to assess gaps in education about exercise, sexual health, fertility, survivorship, financial issues, interpersonal relationships, and clinical trial participation among adolescents and young adults with cancer.\n\nParticipants will be asked to complete a series of questionnaires.",[147,148,149],"Cancer","Young Adult Cancer","Adolescent Cancer",[151,152,147,153,154,155],"Adolescent","Young Adult","AYA","Questionnaire","Needs assessment",{"date":105,"type":35},{"date":158,"type":35},"2026-04-16",{"date":160,"type":20},"2026-10",{"name":41,"class":42},2,{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":21,"phases":172,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":65},"100502654","phase-2-neoadjuvant-chemotherapy-for-borderline-resectable-and-locally-advanced-pancreatic-adenocarcinoma-100502654","NCT05825066","Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma","Inclusion Criteria:\n\n* Patients must have histologically or cytologically proven adenocarcinoma of the pancreas. Patients with mixed tumor with predominant adenocarcinoma pathology can be enrolled.\n* Patients with borderline resectable or locally advanced pancreatic adenocarcinoma as assessed per National Comprehensive Cancer Network (NCCN) guidelines (either pancreatic head, neck, uncinate process, or body\u002Ftail) or institutional multidisciplinary consensus.\n* Age 18 or above.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Patients must have organ and marrow function as defined below:\n\n  * Hemoglobin ≥8 g\u002FdL\n  * Absolute neutrophil count ≥1,500\u002FmcL\n  * Platelets ≥100,000\u002FmcL\n  * Total bilirubin ≤1.5 X institutional upper limit of normal\n  * AST(SGOT)\u002FALT(SGPT) \\\u003C2.5 X institutional upper limit of normal\n  * Creatinine ≤1.5 X institutional upper limit of normal or CrCL\\>50\n  * It is acceptable to transfuse packed red blood cells (PRBC) and platelets at the time of enrollment to meet the eligibility criteria.\n  * If obstructive jaundice is present, consider ursodiol or a biliary drainage procedure. If the total bilirubin can be reduced or kept to less than or equal to 3 mg\u002FdL, then this inclusion criteria is met.\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).\n\nExclusion Criteria:\n\n* Patients who have had prior chemotherapy with gemcitabine and\u002For nab-paclitaxel or FOLFIRINOX for pancreatic cancer.\n* Patients receiving any other investigational anti-neoplastic agents.\n* History of malignancy in last 3 years except cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer, who are considered to be eligible.\n* Patients with active and uncontrolled bacterial, viral or fungal infection requiring systemic therapy. Patients can be reevaluated for the study if the infection is deemed to be under control and the systemic therapy for the infection is completed.\n* Uncontrolled intercurrent illness including, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or compromise the patient's safety.\n* Patients with known diagnosis of interstitial lung disease, sarcoidosis, pulmonary fibrosis, or pneumonitis requiring oxygen supplementation. Those that do not require oxygen supplementation are eligible.\n* Patients who have undergone surgery, other than diagnostic or minor procedures, within 4 weeks prior to the initiation of study treatment.\n* Patients who are pregnant or breastfeeding.",{"count":171,"type":20},64,[173],"PHASE2","The objective of this research is to find out what effects (good and bad), the sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX, the standard chemotherapy for pancreatic cancer, has on participants and their condition. Gemcitabine - Abraxane (nab-Paclitaxel) and mFOLFIRINOX has been approved by the US Food and Drug Administration (FDA) as first line treatment for advanced pancreatic cancer. The sequence of Gemcitabine - Abraxane (nab-Paclitaxel) followed by mFOLFIRINOX has not been approved by the FDA for treatment of pancreatic cancer.",[176,177,178],"Pancreas Adenocarcinoma","Borderline Resectable Pancreatic Adenocarcinoma","Locally Advanced Pancreatic Adenocarcinoma","2026-08-07",{"date":181,"type":35},"2026-08-11",{"date":183,"type":35},"2023-08-01",{"date":185,"type":20},"2028-07",{"name":41,"class":42},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":65},"100382002","pilot-study-of-performance-status-2-vs-performance-status-0-1-non-small-cell-lung-cancer-patients-treated-with-chemoimmunotherapy-100382002","NCT04253964","Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo\u002FImmunotherapy","Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo\u002FImmunotherapy","Inclusion Criteria:\n\n* Patients must have a cytological or histological diagnosis of non-small cell lung cancer that is metastatic or unresectable for which standard curative measures do not exist.\n* No prior systemic treatment with either chemotherapy or immunotherapy for non-curative intent. Patients may have previously received cancer treatment with curative intent for prior early-stage disease.\n* At least 18 years old.\n* ECOG performance status of 0-2, as determined by the treating physician in the consult note.\n* Life expectancy of greater than 3 months.\n* Patients must have normal organ and marrow function as defined below:\n\nabsolute neutrophil count ≥1,000\u002FmcL\n\nplatelets ≥100,000\u002FmcL\n\n* Chemotherapy agents are known to be teratogenic, therefore women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and the willingness to sign an IRB-approved informed consent document.\n\nExclusion Criteria:\n\n* Nonsmall cell lung cancer that is known at registration to be positive for a tumor activating alteration for which first line targeted therapy is indicated; specifically, a targetable mutation in epidermal growth factor receptor (EGFR), gene rearrangement of anaplastic lymphoma kinase (ALK), gene rearrangement of c-ros oncogene 1 (ROS1), or mutation in B isoform of rapidly accelerated fibrosarcoma (B-Raf). For non-squamous subtypes, molecular testing of tumor and peripheral blood should be attempted for actionable biomarkers, but if there is an insufficient quantity of tumor material for testing and it is not feasible to attempt additional biopsies before starting systemic therapy, then these biomarker results are not necessary for inclusion on the study. For squamous subtype, molecular testing should be considered but is not necessary for inclusion on the study.\n* Known to have an active autoimmune disease that required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, systemic corticosteroids, or immunosuppressive drugs).\n* History of (non-infectious) pneumonitis that required systemic corticosteroids.\n* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects with chemotherapy. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued.",{"count":195,"type":20},105,[173],"This pilot study is configured as a non-inferiority comparison of Performance Status 2 patients with Performance Status 0-1 patients, with the goal of demonstrating non-inferiority in terms of efficacy (progression-free survival, overall survival) and safety (rates of adverse events, quality of life) when treating Performance Status 2 patients with the same first-line immunotherapy-based regimen as Performance Status 0-1 patients.",[199,200],"Nonsmall Cell Lung Cancer","Performance Status","2026-08-06",{"date":103,"type":35},{"date":204,"type":35},"2020-07-01",{"date":206,"type":20},"2027-09-01",{"name":41,"class":42},{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":16,"minAge":216,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":230,"completionDateStruct":231,"leadSponsor":233,"locationsCount":65},"100651059","restoring-vascular-and-insulin-function-to-augment-anti-amyloid-therapy-in-alzheimers-disease-100651059","NCT07756294","Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease","REstoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in ALZheimer'ss Disease (REVITAA-ALZ): A Placebo-controlled Trial of Intranasal Insulin vs. Empagliflozin in Mild Cognitive Impairment (MCI) or Early Alzheimer's Disease (AD) Treated With Anti-Amyloid Targeting Therapy (Lecanemab or Donanemab)","REVITAA-ALZ","Inclusion Criteria:\n\n* Fluent in English\n* Diagnosis of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease via previously documented clinical assessment\n* Amyloid positive by PET or cerebrospinal fluid criteria\n* Stable medical condition for 3 months prior to screening visit\n* Stable medications for general medical conditions for 4 weeks prior to the screening and study visits (exceptions may be made on a case-by-case basis by study clinician)\n* Stable on Anti-Amyloid Targeting Therapy (lecanemab or donanemab) for at least 8 weeks prior to Baseline Visit\n* If receiving an acetylcholinesterase inhibitor (donepezil, rivastigmine, galantamine) or memantine or both, must be stable on a dose for at least 30 days prior to Baseline Visit\n* Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the study clinician\n* Participants must have a study partner who agrees to participate throughout the duration of the study. The study partner must have frequent and sufficient contact (approximately 10 hours per week) with the participant and be able to provide accurate information regarding the participant's cognitive and functional abilities.\n\nExclusion Criteria:\n\n* A diagnosis of dementia other than Alzheimer's disease\n* History of a clinically significant stroke, history of transient ischemic attack within 12 months, or any history of seizures\n* Current evidence or history in past two years of head injury with loss of consciousness, any major psychiatric disorder including psychosis, unstable major depressive disorder, bipolar disorder\n* Diabetes (type I or type II) insulin dependent and non-insulin dependent diabetes mellitus\n* Current or past regular use of insulin or any other anti-diabetic medication within 2 months of screening visit\n* Cancer within the past 2 years with the exception of non-melanoma skin cancers and non-metastatic prostate cancer that has been stable for at least 6 months\n* Pregnancy or possible pregnancy\n* Use of anticoagulants\n* Residence in a skilled nursing facility at screening\n* Use of an investigational agent within two months of screening visit\n* Regular use of alcohol, narcotics, anticonvulsants, anti-Parkinsonian medications, or any other exclusionary medications (exceptions may be made on a case-by-case basis by study clinician)\n* Any history of immunologic disease (e.g. lupus, rheumatoid arthritis, Crohn's disease) or systemic treatment with immunosuppressants, immunoglobulins, or monoclonal antibodies or their derivatives\n* History of a bleeding disorder that is not under adequate control, including a platelet count less than 50,000 or INR greater than 1.5\n* Contraindications for MRI, including claustrophobia or the presence of contraindicated metal implants\u002Fcardiac pacemaker\n* Baseline MRI Findings: More than four microhemorrhages defined as 10mm or less at the greatest diameter; A single macro hemorrhage greater than 10mm at greatest diameter; An area of superficial siderosis; Evidence of vasogenic edema; More than two lacunar infarcts or stroke involving a major vascular territory; Severe subcortical hyperintensities consistent with Fazekas score of 3; Evidence of amyloid beta-related angiitis (ABRA); Cerebral amyloid angiopathy (CAA); Cerebral contusion, encephalomalacia, brain aneurysm or other vascular malformations, central nervous system infection, brain tumor, or other major intracranial pathology that may cause cognitive impairment","55 Years","85 Years",{"count":219,"type":20},30,[173],"The purpose of this study is to find out what effects (good and bad) the study medications (insulin or Empagliflozin) have on adults with mild memory impairment or early Alzheimer's disease who are clinically prescribed an anti-amyloid therapy compared to placebo.",[223],"Alzheimer Disease",[225,226,227],"mild cognitive impairment","mild dementia","insulin","2026-08-05",{"date":103,"type":35},{"date":132,"type":20},{"date":232,"type":20},"2028-04",{"name":41,"class":42},{"id":235,"slug":236,"hasResults":12,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":162},"100559712","cancer-related-fatigue-during-maintenance-immunotherapy-for-non-small-cell-lung-cancer-nsclc-a-qualitative-study-100559712","NCT06567704","Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study","Inclusion Criteria:\n\n* ≥ 18 years of age at the time of consent.\n* Must be able to speak, read, and understand English.\n* Participants diagnosed with NSCLC, and:\n\n  * have advanced\u002Fmetastatic disease who are currently receiving immunotherapy monotherapy, or\n  * have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or\n  * who underwent resection and are currently receiving immunotherapy monotherapy after completing all other perioperative treatment\n* Immunotherapy planned to continue for at least three months after the time of study enrollment (to ensure participant remains on IO long enough to obtain study assessments)\n* Have completed at least two cycles of immunotherapy.\n* Self-reported cancer-related fatigued that impacts daily function.\n\nExclusion Criteria:\n\n* Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months\n* Participants who have received radiation therapy within the past 3 months. Note: a short course of palliative radiation therapy within up to 20 Gy and up to 5 fractions is permissible.\n* Diagnosis of dementia.\n* Anemia Hgb \\\u003C10 g\u002FdL.\n* Sarcopenia which is being pharmacologically treated with a prescribed appetite stimulant (e.g., megestrol).\n* Untreated hypothyroidism.\n* Symptomatic heart failure.\n* Oxygen dependent lung disease.\n* Cognitively unable to complete interviews per investigator.",{"count":241,"type":20},20,"The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.",[244],"Non-small Cell Lung Cancer",[246,247],"Cancer related fatigue","Immune checkpoint inhibitor",{"date":103,"type":35},{"date":250,"type":35},"2025-03-26",{"date":252,"type":20},"2027-07",{"name":41,"class":42},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":270,"startDateStruct":271,"completionDateStruct":273,"leadSponsor":275,"locationsCount":276},"100502943","incremental-hemodialysis-the-twoplus-trial-100502943","NCT05828823","Incremental Hemodialysis: The TwoPlus Trial","Comparative Effectiveness of an Individualized Model of Hemodialysis Versus Conventional Hemodialysis","Patient eligibility Criteria:\n\nInclusion Criteria:\n\n* Clinical Inclusion Criteria:\n* Age ≥ 18 years\n* Incident kidney dysfunction requiring dialysis (KDRD) started on maintenance, in-center hemodialysis (HD), or anticipated to be started on maintenance, in-center HD within the next 12 weeks\n* Has received ≤36 sessions of intermittent HD (i.e., on HD for ≤12 weeks) at the time patient is approached for potential study participation\n\nResidual Kidney Function Inclusion Criteria:\n\n* Kidney urea clearance ≥ 2.0 mL\u002Fmin\n* Urine volume# of ≥500 mL\u002F24 h\n\nExclusion Criteria:\n\n* Pre-HD serum K ≥5.8 mEq\u002FL, Na ≤125 mEq\u002FL, or bicarbonate level ≤17 mEq\u002FL\n* Requirement or anticipated requirement of high-volume ultrafiltration\n* Unable or unwilling to follow the study protocol for any reason\n* Known pregnancy or planning to attempt to become pregnant or lactating women\n* Estimated survival or dialysis modality change or center transfer \\\u003C6 months\n\nCaregiver Eligibility Criteria:\n\n* be at least 18 years old\n* be the main caregiver (at patient's choice)\n* be a close relative of the patient (spouse, child, sibling, parent, grandchild)\n* have no known psychiatric and neurologic disorders (through direct inquiry from the person)\n* not be a member of the medical or healthcare team\n* not be the caregiver for another patient with chronic illness\n* not have experienced severe life events within prior 3 months of enrollment (through direct inquiry from the person)",{"count":262,"type":20},350,[76],"This study is to prospectively compare clinical effectiveness between clinically- matched incremental hemodialysis and conventional hemodialysis in patients with incident kidney dysfunction requiring dialysis and residual kidney function.\n\nThe study will enroll 350 patients on chronic hemodialysis and 140 caregivers of enrolled patients. Patients will be randomized in 1:1 ratio to either incremental start hemodialysis or conventional hemodialysis. Caregivers will be followed along with patients for an average period of 2 years post randomization.",[266],"End-Stage Kidney Disease",[268,269],"Hemodialysis","Clinically-Matched Incremental Hemodialysis",{"date":201,"type":35},{"date":272,"type":35},"2024-02-26",{"date":274,"type":20},"2031-01",{"name":41,"class":42},10,{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":21,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":295,"completionDateStruct":296,"leadSponsor":298,"locationsCount":65},"100602707","mindfulness-in-nonflaccid-facial-paralysis-100602707","NCT07127016","Mindfulness in Nonflaccid Facial Paralysis","Inclusion Criteria:\n\n\\- Diagnosed with non-flaccid facial paralysis (NFFP) due to Bell's Palsy, Ramsay Hunt syndrome, Lyme disease, or post-acoustic neuroma resection, at least 8 months from the initial diagnosis\n\nExclusion Criteria:\n\n* Received treatments such as botox or physical therapy for facial paralysis\n* History of malignancy or facial surgery",{"count":284,"type":20},24,[76],"The purpose of this study is to learn more about how mindfulness techniques can help reduce anxiety, depression and body image disturbance as well as improve synkinesis in individuals with non-flaccid facial paralysis.",[288],"Facial Paralysis",[290,291,292],"non-flaccid facial paralysis","synkinesis","mindfulness","2026-08-04",{"date":228,"type":35},{"date":132,"type":20},{"date":297,"type":20},"2027-01",{"name":41,"class":42},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":306,"targetDuration":4,"studyType":21,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":320,"locationsCount":65},"100623037","assessing-psoriasis-treatment-outcomes-100623037","NCT07391423","Assessing Psoriasis Treatment Outcomes","Assessing Psoriasis Treatment Outcomes: a Single-center, Prospective Study Evaluating Patient Outcomes in Psoriasis","Inclusion Criteria:\n\n* Patients ≥18 years of age\n* Patients with a current diagnosis of psoriasis suitable for treatment with topical Betamethasone (BD)\n* Patients who live in the United States\n* Patients with a sufficient command of the English language\n* Patients with a mobile device able to at least operate at 25 frames per second (FPS).\n\nExclusion Criteria:\n\n* Patients less than the age of 18\n* Patients with severe or unstable comorbid conditions\n* Patient who are pregnant or breastfeeding\n* Patients with any other skin conditions that prohibit or confound the ability of the investigator to interpret skin findings\n* Patients that are taking concomitant topical or systemic therapy for the treatment of psoriasis and\u002For phototherapy\n* Patients without mobile devices able to at least operate at 25 frames per second (FPS).\n* Patients without a current diagnosis of psoriasis suitable for treatment with topical BD",{"count":43,"type":20},[76],"To assess the feasibility of AIGPP video interactions with psoriasis patients. To explore patient attitudes, trust, and comfort levels concerning AIGPP interactions in a healthcare setting, and to understand their influence on the patient-physician dynamic. To evaluate medication adherence over a 4-week period in patients with psoriasis randomized to weekly AI-generated automated physician providers (AIGPP) video interactions, weekly human video calls, or standard care (single follow up visit after 4 weeks). Adherence rates will be evaluated via a cap designed to record adherence attached to the study medication container.",[310],"Psoriasis",[312,313,314],"Psoriasis Treatment Outcomes","medication adherence","Artificial intelligence","2026-08-03",{"date":293,"type":35},{"date":160,"type":20},{"date":319,"type":20},"2029-03",{"name":41,"class":42},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":16,"minAge":329,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":21,"phases":333,"briefSummary":335,"conditions":336,"keywords":338,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":344,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":348,"locationsCount":65},"100591973","phase-3-vibegron-for-energy-thinking-and-resilience-in-aging-100591973","NCT06987383","Vibegron for ENergy Thinking and Resilience in Aging","Vibegron - A Novel Treatment for Multisystem Functional Decline in Aging and Obesity","VENTURA","Inclusion Criteria:\n\n* Obese (BMI ≥30 kg\u002Fm2 or BMI ≥27 kg\u002Fm2 with a waist circumference \\>102 cm for men and \\>88 cm for women)\n\nExclusion Criteria:\n\n* Body weight ≥450 pounds\n* Major depression\n* Evidence of cognitive impairment\n* Uncontrolled diabetes (hemoglobin A1c \\>7%)\n* Weight gain or loss of ≥5% over the past 6 months\n* Prior weight loss procedure (e.g., gastric bypass, sleeve gastrectomy, gastric banding)\n* Regular use of the following: weight loss medications (e.g., Orlistat, Belviq, Contrave, Saxenda, Phentermine, Qsymia); medications or dietary supplements known to alter energy metabolism; adrenergic agonists or beta blockers\n* Symptoms of urinary retention, incontinence, urgency, and frequency or current use of an antimuscarinic medication to treat overactive bladder\n* Benign prostate hyperplasia\n* Significant medical illness or organ failure, such as uncontrolled hypertension, advanced kidney disease, liver disease, thyroid disease, or active neoplastic disease\n* Diagnosis of a neurodegenerative illness (e.g., mild cognitive impairment, dementia, Parkinson's disease, Multiple Sclerosis)\n* History of a clinically significant stroke\n* Cardiac arrhythmia or an abnormal Electrocardiogram\n* Drug\u002Fsubstance abuse or excessive alcohol use within the past 6 months\n* Contraindication to Vibegron or any of its components\n* Current participation in another intervention or research study that prohibits co-enrollment","45 Years","75 Years",{"count":332,"type":20},40,[334],"PHASE3","This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.",[337],"Obesity",[339,340,341,342,343],"Vibegron","aging","metabolism","physical function","cognitive function",{"date":293,"type":35},{"date":346,"type":20},"2026-09",{"date":185,"type":20},{"name":41,"class":42},{"id":350,"slug":351,"hasResults":12,"nctId":352,"briefTitle":353,"officialTitle":353,"acronym":4,"eligibilityCriteria":354,"healthyVolunteers":12,"sex":16,"minAge":355,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":21,"phases":357,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":65},"100534852","topical-treatment-for-atopic-dermatitis-100534852","NCT06244212","Topical Treatment for Atopic Dermatitis","Inclusion Criteria:\n\n* Diagnosis of skin dermatitis\n* Age \\> 9\n* Ability to return for a one-week clinical studies follow-up\n* Patients who are candidates for treatment with 0.1% triamcinolone ointment (even if they weren't in the study)\n* Adult or pediatric patients with active dermatitis who receive dermatologic care at Atrium Health Wake Forest Baptist, Department of Dermatology.\n\nExclusion Criteria:\n\n* Patients without the diagnosis of skin dermatitis\n* Inability to return for a one week follow up appointment\n* Body Surface Area (BSA) affected \\\u003C2%","9 Years",{"count":219,"type":20},[76],"Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admission costs. While the issue of adherence is not limited to any particular field of medicine, non-adherence occurs in approximately one-third to one-half of dermatological patients. Non-adherence is of importance as it is a significant cause of treatment failure, resulting in worse quality of life, worse health outcomes, and increased insurance costs.",[360],"Atopic Dermatitis",[362,363,364],"Medication adherence","topical medications","Triamcinolone",{"date":293,"type":35},{"date":367,"type":35},"2024-09-19",{"date":369,"type":20},"2027-11",{"name":41,"class":42},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":377,"minAge":17,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":21,"phases":379,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":390,"leadSponsor":391,"locationsCount":65},"100322193","early-phase-1-evaluating-the-efficacy-of-platelet-rich-plasma-therapy-in-the-treatment-of-androgenic-alopecia-100322193","NCT03474718","Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia","Inclusion Criteria:\n\n* Female ≥18 years of age at baseline visit.\n* Documentation of androgenic alopecia diagnosis as evidenced by one or more clinical features\n* Not currently on any treatment for alopecia, or has undergone 2-week washout period if recently on medication(s) for alopecia\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n* Have an infection, metastatic disease or certain skin conditions (ie. Psoriasis) which could worsen or spread with injections\n* Diagnosed with a blood or bleeding disorder\n* Diagnosed with anemia\n* Currently on anticoagulant therapy","FEMALE",{"count":74,"type":20},[380],"EARLY_PHASE1","The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.",[383],"Androgenic Alopecia",[385,386,387],"scalp","hair loss","platelet-rich plasma therapy",{"date":293,"type":35},{"date":160,"type":20},{"date":252,"type":20},{"name":41,"class":42},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":402,"conditions":403,"keywords":409,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":65},"100434950","human-immunodeficiency-virus-hiv-food-insecurities-100434950","NCT04943861","Human Immunodeficiency Virus (HIV) Food Insecurities","Exploring the Consequences of Food Insecurity and Harnessing the Power of Peer Navigation and mHealth to Reduce Food Insecurity and Cardiometabolic Comorbidities Among Persons With HIV","Inclusion Criteria:\n\n* participant must be a patient of the Wake Forest Infectious Diseases Specialty Clinic\n* be living with HIV\n* ≥18 years of age\n* provide informed consent\n\nExclusion Criteria:\n\n* unable to speak English or Spanish\n* have cognitive impairment that would prevent participation",{"count":400,"type":20},200,[76],"The objectives of this study are to better understand how FI (food insecurities) contributes to the development of cardiometabolic comorbidities among PWH (People with HIV) and to test a novel bilingual FI intervention designed to reduce these comorbidities among food insecure PWH. The PI and staff will conduct this study in partnership with the Wake Forest Infectious Diseases Specialty Clinic, one of the largest Ryan White-funded clinics in North Carolina, which serves more than 2,000 PWH annually from a predominantly rural catchment area that includes South Central Appalachia. This area has high rates of both FI and HIV.",[404,405,406,407,408],"Food Insecurities","Cardiometabolic Comorbidities","HIV","PreDiabetes","Type 2 Diabetes Mellitus (T2DM)",[410],"Food Insecurity","2026-07-31",{"date":293,"type":35},{"date":414,"type":35},"2023-12-01",{"date":416,"type":20},"2027-02-28",{"name":41,"class":42},{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":12,"sex":377,"minAge":17,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":21,"phases":427,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":438,"leadSponsor":439,"locationsCount":65},"100335950","patient-centered-simulation-for-labor-and-delivery-100335950","NCT03654079","Patient Centered Simulation For Labor and Delivery","Inclusion Criteria:\n\n* Nulliparous pregnant women\n* In third trimester\n\nExclusion Criteria:\n\n• Not planning on delivering with Wake Forest School of Medicine OB\u002FGYN","44 Years",{"count":426,"type":20},50,[76],"Patient satisfaction is an important outcome in the evaluation and development of healthcare services. Studies have identified tools that successfully measure women's childbirth experiences, and have shown that multidimensional measures of women's satisfaction in labor and delivery provides a richer and diverse perspective on women's experiences of intrapartum care. Childbirth experience can have significant effects, both positive and negative, on women's immediate and long term health outcomes. Patients with negative experiences surrounding childbirth have been shown to have significant fear surrounding the labor and delivery experience that negatively impact subsequent deliveries. Often fear is worsened by a lack of knowledge of what to expect during labor. Women enrolled in this study will simulate some of the potentially stressful experiences that commonly occur during labor to determine if doing so decreases a woman's fear and anxiety about labor and delivery.",[430],"Pregnancy Related",[432,433,434,435],"Simulation","Pregnancy","Labor and Delivery","Childbirth",{"date":411,"type":35},{"date":297,"type":20},{"date":369,"type":20},{"name":41,"class":42},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":21,"phases":448,"briefSummary":449,"conditions":450,"keywords":452,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":459,"leadSponsor":460,"locationsCount":65},"100649287","phase-4-pelashield-vs-xeroform-100649287","NCT07734519","Pelashield vs Xeroform","A Prospective Randomized Split-Site Study of Donor-Site Pain and Appearance Following Pelashield TM Versus Xeroform","Inclusion Criteria:\n\n* Undergoing split-thickness skin graft harvest, with a donor site sufficiently large to allow division into two comparable halves for randomized dressing application.\n* Donor site located in an area amenable to standardized photography and serial appearance assessment.\n* Ability to provide informed consent.\n* Willingness and ability to participate in scheduled follow-up visits for donor-site assessment, including standardized photography.\n* Donor-site management expected to follow the standardized study dressing protocol for the duration of the early healing period.\n\nExclusion Criteria:\n\n* Inability, or anticipated inability, to reliably report pain within 1hour (or in recovery room) after surgery\n* Known allergy or hypersensitivity to lidocaine, silver-containing dressings, or other components of the study dressings.\n* Donor sites that are too small, irregularly shaped, or anatomically unsuitable to allow division into two comparable treatment halves.\n* Pre-existing skin disease at or adjacent to the donor-site region that may affect wound healing or scar appearance\n* Clinical situations in which the treating surgeon anticipates that protocol-based donor-site care cannot be maintained, including cases requiring non-standard dressings or adjunctive local therapies.\n* Anticipated inability to complete follow-up assessments, including inability to obtain evaluable standardized photographs at key time points.\n* Severe uncontrolled systemic conditions likely to significantly impair wound healing, at the discretion of the investigator (e.g., severe immunosuppression or other conditions making reliable donor-site healing unlikely).\n* Allergy to any local anesthetic\n* Allergy or sensitivity to silver\n* Pregnancy",{"count":332,"type":20},[23],"The purpose of this research study is to compare the effects (good or bad) of a new skin graft dressing (PelashieldTM) compared to the one traditionally used (Xeroform).",[451],"Skin Graft",[453,454,455],"Pelashield","Xeroform","donor site pain","2026-07-29",{"date":411,"type":35},{"date":132,"type":20},{"date":252,"type":20},{"name":41,"class":42},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":21,"phases":469,"briefSummary":470,"conditions":471,"keywords":473,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":483},"100641567","comparing-two-acute-care-transition-programs-for-older-adults-and-their-family-caregivers-100641567","NCT07661355","Comparing Two Acute Care Transition Programs for Older Adults and Their Family Caregivers","Patient Inclusion Criteria:\n\n* 65 and older\n* English and Spanish speaking\n* Preadmission location: community dwelling\n* Distance from Hospital: Local and Distant (rural) included\n* Cognitive impairment, dementia allowed\n* Technology Literacy: Flexible from high to low\n* EPIC readmission risk score over 12\n* Discharged home\n\nPatient Exclusion Criteria:\n\n* Admitted from skilled nursing facility\n* Discharged to skilled nursing facility\n* Left Against Medical Advice (AMA)\n* Planned readmission\n* Died during index admission\n* Caregiver unwilling to participate\n\nCaregiver Inclusion Criteria:\n\n* Adults 18 and older\n* English and Spanish speaking\n* Providing tangible support to patient\n* Distance from Hospital: Local and Distant (rural) included\n* Only Mild Cognitive Impairment allowed\n* Able to be trained in Video Visit Technology\n* Available to support post-discharge\n\nCaregiver Exclusion Criteria:\n\n• Has a greater than a mild cognitive impairment (\\\u003C 12 on MCA)",{"count":468,"type":20},2560,[76],"This study investigates better ways to help people after they leave the hospital and how to involve their families in this process. The main goal is to see if adding family support to a patient-centered hospital-to-home intervention helps patients stay safely at home, spend fewer days back in the emergency room or going back into the hospital. The study team also wants to see if the family-centered approach helps improve the patient's ability to do everyday activities without feeling overwhelmed. Two approaches are being compared: one focuses just on the patient, and the other includes special strategies to better support families involved too. Family will be involved in assessing what the patient and family needs. The family-focused approach not only emphasizes the experience, health, and safety of the patient but also the experience of the family member caring for the older adult. The study also involves families in education and provides families skills-building experiences that can help with caregiving stress, problem-solving, and communicating with the healthcare team. The approach will help the family member prepare for their loved one's transition home and provide coaching with the goal of reducing the mental, physical and financial burden of providing care at home. To spread the intervention across many states, the study team will be using telephone calls, video calls, and other technologies as families prefer.",[472],"Care Transition",[474,475,340,476,225],"hospitalization","older adults","care transition",{"date":411,"type":35},{"date":479,"type":35},"2026-07-22",{"date":481,"type":20},"2031-11",{"name":41,"class":42},4,{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":21,"phases":492,"briefSummary":493,"conditions":494,"keywords":496,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":500,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":504,"locationsCount":65},"100632653","thermal-preconditioning-in-mastectomy-patients-with-immediate-breast-reduction-100632653","NCT07516483","Thermal Preconditioning in Mastectomy Patients With Immediate Breast Reduction","Thermal Preconditioning in Patients Undergoing Mastectomy With Planned Immediate Breast Reconstruction: A Randomized Feasibility Trial","Inclusion Criteria:\n\n* Adult patients (≥ 18 years of age) undergoing prophylactic or therapeutic mastectomy with planned immediate breast reconstruction at Atrium Health Wake Forest Baptist Medical Center.\n\nExclusion Criteria:\n\n* Patients with no plan for any breast reconstruction.\n* Patients with inflammatory breast cancer.\n* History of any radiation to the breast or chest wall.\n* Patients with pre-existing local dermatological conditions.\n* Patients belonging to vulnerable populations (e.g., children, pregnant individuals, incarcerated persons).\n* Patients unable to provide informed consent or comply with study procedures.",{"count":332,"type":20},[76],"The purpose of this research study is to understand patient experiences and the feasibility of using a breast heat preconditioning device (Plexaa BLOOM43), designed to improve postoperative outcomes when used prior to mastectomy and breast reconstruction.",[495],"Breast Reconstruction After Mastectomy",[497,498,499],"heat preconditioning","mastectomy","breast reconstruction",{"date":107,"type":35},{"date":132,"type":20},{"date":503,"type":20},"2027-05",{"name":41,"class":42},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":512,"targetDuration":4,"studyType":21,"phases":513,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":65},"100522025","immersive-healing-the-therapeutic-potential-of-virtual-reality-100522025","NCT06077227","Immersive Healing: The Therapeutic Potential of Virtual Reality","Immersive Healing: The Therapeutic Potential of Virtual Reality in Phantom Limb Experience","Inclusion Criteria:\n\n* History of major limb amputation\n* Age \\> 18 years old\n* Presence of phantom limb pain or negative phantom sensation(s)\n\nExclusion Criteria:\n\n* Active mental illness, neurological disease, or cognitive impairment that would interfere with survey completion\n* Those without phantom limb pain or negative phantom limb sensations\n* Non-English speaking",{"count":241,"type":20},[76],"Phantom limb pain (PLP) is a significant and pervasive issue among upper limb amputees, severely impacting their quality of life. The literature delineating prevalence of upper versus lower limb amputations is limited, but the prevalence of total amputations in the United States is estimated to reach 3 million individuals by 2050, with approximately 185,000 new cases annually. PLP affects 60-68% of these patients, leading to heightened levels of anxiety, depression, and reduced overall well-being.",[516],"Phantom Limb Pain (PLP)",[518,519,520],"amputee","pain management","virtual reality (VR) therapy",{"date":411,"type":35},{"date":523,"type":35},"2023-12-21",{"date":160,"type":20},{"name":41,"class":42},{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":532,"eligibilityCriteria":533,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":534,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":535,"conditions":536,"keywords":540,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":545,"leadSponsor":547,"locationsCount":65},"100649825","neurocognitive-trajectories-after-bcma-car-t-100649825","NCT07740317","Neurocognitive Trajectories After BCMA CAR-T","Longitudinal Neurocognitive Trajectories After BCMA CAR-T in Multiple Myeloma","CAR-T Cog","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign an IRB-approved informed consent\n2. Ability to retain independent decision-making capacity as per the enrolling investigator\n3. Age ≥ 18 years of age at the time of consent\n4. Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician\n5. Ability to read and understand the English language\n6. ECOG 0-2\n7. If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician\n8. Reliable access to internet access; a tablet, laptop and\u002For desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report\n9. Ability to complete required assessments, as determined by the treating clinician\n\nExclusion Criteria:\n\n1. Active central nervous system (CNS) disease\n2. Known neurodegenerative disease or major neurocognitive disorder\n3. Stroke and\u002For traumatic brain injury (TBI) within 12 months\n4. Concurrent investigational neuroactive drugs",{"count":426,"type":20},"The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).",[537,538,539],"Multiple Myeloma (MM)","CART Therapy","Refractory Multiple Myeloma (RRMM)",[541],"cancer","2026-07-28",{"date":411,"type":35},{"date":346,"type":20},{"date":546,"type":20},"2029-11",{"name":41,"class":42},{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":553,"acronym":4,"eligibilityCriteria":554,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":555,"targetDuration":4,"studyType":21,"phases":557,"briefSummary":558,"conditions":559,"keywords":561,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":567,"leadSponsor":569,"locationsCount":65},"100611903","phase-4-lumbar-drain-with-intrathecal-nicardipine-in-aneurysmal-subarachnoid-hemorrhage-100611903","NCT07246629","Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage","Prophylactic Use of Intrathecal Calcium Channel Antagonist Through Lumbar Drain in Patients With Subarachnoid Hemorrhage Due to Aneurysmal Rupture","Inclusion Criteria:\n\n* Age ≥18 years\n* Aneurysmal subarachnoid hemorrhage with Hunt and Hess score 3 or less\n* Patient or legal authorized representative available to sign the informed consent form\n* Pre-morbid modified Rankin scale of 0 or 1.\n* Patients who have lumbar drain placed or planned for cerebrospinal fluid diversion per standard of care\n* Patients who are able to be randomized within 72 hours from arrival with aneurysmal subarachnoid hemorrhage or within 24 hours from lumbar drain placement\n\nExclusion Criteria:\n\n* Pregnant females\n* Subarachnoid hemorrhage (SAH) with hunt and hess scale of \\>3\n* SAH due to etiology other than aneurysmal rupture\n* Any contraindications in patients receiving calcium channel antagonists like hypersensitivity to dihydropyridines\n* Active central nerve infection (CNS) infection or high suspicion of CNS infection\n* Hemodynamic instability preventing the use of Nicardipine",{"count":556,"type":20},214,[23],"The purpose of this study is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms.",[560],"Subarachnoid Hemorrhage",[562,563,564],"cerebral aneurysm","intrathecal nicardipine","vasospasm",{"date":107,"type":35},{"date":346,"type":20},{"date":568,"type":20},"2027-03",{"name":41,"class":42},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":377,"minAge":578,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":162},"100596551","role-of-mitochondrial-bioenergetics-in-resilience-for-gynecologic-cancer-100596551","NCT07046936","Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer","The Role of Mitochondrial Bioenergetics in Resilience in Older Adults With Gynecologic Cancer Receiving Cancer Reductive Treatment","MITO-RES","Inclusion Criteria:\n\n* Ability to understand and willingness to sign an IRB-approved informed consent\n* Age ≥50 years at the time of enrollment\n* Newly diagnosed or suspected FIGO Stage II-IV ovarian\u002Fprimary peritoneal\u002Ffallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype\n* Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy OR tumor reduction surgery with adjuvant chemotherapy\n* Ability to read and understand the English language\n\nExclusion Criteria:\n\n* Previously treated for ovarian or endometrial cancer\n* History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia\n* Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator\n* Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study","50 Years",{"count":219,"type":20},"The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.",[582],"Gynecologycal Cancer",[584,147],"Mitochondrial Bioenergetics",{"date":107,"type":35},{"date":587,"type":35},"2026-03-10",{"date":589,"type":20},"2027-04",{"name":41,"class":42},""]